REGENERON Aktie

 

They could both outperform the market over the medium term, but one appears to have a clear edge....

Guarini, Kathryn - Aufsichtsrat - Tag der Transaktion: 2026-09-02...

Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-03...

Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-02...

SAN DIEGO, Sept. 3, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until September 14, 2026 to seek......

SAN FRANCISCO, Sept. 3, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

Market impact notice: REGN shares allegedly lost $102.09 from the Class Period high after disclosures about a Phase III Fianlimab-Libtayo protocol change and failed primary endpoint challenged earlier positive trial-risk messaging. NEW YORK, Sept. 3, 2026 /PRNewswire/ -- SueWallSt......

Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing event accrual as potentially favorable, even as the study allegedly faced heightened risk of......

SAN FRANCISCO, Sept. 1, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980,......

Control-person liability allegations focus on Regeneron executives' alleged authority over public clinical-trial statements and SEC disclosures as REGN shares fell $102.09 from the Class Period high. NEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt notifies investors in Regeneron......

SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

This promise-vs-reality notice focuses on allegations that Regeneron promoted Phase I Fianlimab-Libtayo results and practice-changing expectations while the Phase III study allegedly faced heightened statistical and clinical failure risk. NEW YORK, Aug. 26, 2026 /PRNewswire/ -- Levi &......

Leading biopharma company selects agentic CRM for life sciences to generate Commercial Evidence PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally. With Vault CRM, Regeneron......

SAN FRANCISCO, Aug. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......

This Regeneron analyst reaction focuses on analysts' reassessment of the Phase III Fianlimab-Libtayo Study after a protocol amendment raised concerns about statistical significance and potential impact on Regeneron's pipeline and future growth expectations. NEW YORK, Aug. 20, 2026......

REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups....

SAN FRANCISCO, Aug. 20, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......